Viral Vectors and Plasmid DNA Market Report 2025

The viral vectors and plasmid dna market size has grown rapidly in recent years. It will grow from $1.05 billion in 2024 to $1.2 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to increasing prevalence of cancer, growing awareness of gene therapy, growing patient population, increased access to healthcare, growing demand for personalized medicine.

The viral vectors and plasmid dna market size is expected to see strong growth in the next few years. It will grow to $1.66 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to emerging therapeutic applications, COVID-19 pandemic response, increased funding, global expansion. Major trends in the forecast period include advances in viral vector and plasmid DNA manufacturing technology, advances in gene editing, customized vectors, scalability and production efficiency, safety and quality standards, non-viral delivery methods, international collaboration.

The global surge in cancer cases is a significant driving force behind the growth of the viral vector and plasmid DNA market. Common cancer triggers like obesity, smoking, alcohol consumption, and poor dietary habits contribute to the majority of cancer diagnoses. As projected by the American Cancer Society in January 2022, the US will likely witness 1.9 million new cancer cases and approximately 609,360 cancer-related deaths in the same year. Globally, lung, prostate, bowel, and female breast cancers are the most prevalent, accounting for 43% of all new cancer cases. This rise in cancer incidence is anticipated to bolster the demand for viral vectors and plasmid DNA in the market.

The increasing prevalence of tuberculosis cases is also driving growth in the viral vector and plasmid DNA market. Tuberculosis, an infectious disease caused by bacteria, primarily affects the lungs but can extend to other body parts. Plasmid DNA vaccines, delivering microbial antigen-coding genes for tuberculosis, have shown promise in combating this disease. These vaccines can express specific antigens of Mycobacterium tuberculosis, the causative bacterium, through intramuscular injection. According to the Centers for Disease Control and Prevention's March 2023 report, the US witnessed a rise in tuberculosis cases from 7,874 in 2021 to 8,300 in 2022, emphasizing the driving force of tuberculosis cases in the growth of the viral vector and plasmid DNA market.

Companies in the viral vectors and plasmid DNA market are strategically launching viral vector assays to invigorate gene therapy research. Viral vectors, essential in delivering genetic material into cells, are complemented by viral vector assays, investigative procedures that analyze these vectors. For instance, in November 2022, PerkinElmer introduced 'ready-to-use' adeno-associated virus vectors (AAV) detection kits. These aids support researchers involved in gene therapy across diverse diseases by facilitating the quick and efficient characterization of viral vector particles, guiding safe and effective gene transfer decisions.

Major players in the viral vectors and plasmid DNA market are intensifying their efforts toward product innovation, notably helper plasmids, to gain a competitive edge. Helper plasmids, a form of plasmid DNA utilized in producing viral vectors like adeno-associated viral vectors (AAV), are pivotal in gene therapy. For instance, Charles River Laboratories International Inc. unveiled off-the-shelf pHelper in March 2023. This innovation streamlines the process of developing adeno-associated virus (AAV)-based gene therapy programs, minimizing complexities and expediting supply chains. pHelper, part of a comprehensive line of contract development and manufacturing organization (CDMO) offerings, serves to fortify viral vector packaging in cell and gene therapy endeavors, particularly in creating adeno-associated viral vectors essential for gene therapy.

In January 2023, Moderna Inc., a pharmaceutical and biotechnology company based in the US, finalized the acquisition of OriCiro Genomics for $85 million. This strategic acquisition aims to expedite Moderna's pipeline development by enhancing their capabilities in plasmid DNA synthesis and amplification, which serves as a crucial foundation for manufacturing messenger RNA (mRNA). OriCiro Genomics, a Japan-based genome technology company, specializes in developing and commercializing cell-free systems designed for assembling and amplifying circular DNA molecules, notably plasmids and viral vectors. This acquisition positions Moderna to strengthen its mRNA production processes with advanced tools provided by OriCiro Genomics.

Viral vectors are tools constructed from viral genomes adapted into plasmid-based technologies. They are modified for safety by removing specific essential genes and separating viral components. On the other hand, plasmid DNA refers to small, circular DNA molecules present in certain bacteria and other microorganisms. These plasmids are physically distinct from chromosomal DNA and can replicate independently.

The primary product types within the viral vectors & plasmid DNA domain include plasmid DNA and viral vectors. Plasmids are circular DNA molecules separate from a cell's chromosomal DNA, commonly found in bacterial and some eukaryotic cells. Plasmid genes often confer genetic advantages to bacteria, such as antibiotic resistance.

The viral vectors & plasmid DNA market research report is one of a series of new reports that provides viral vectors & plasmid DNA market statistics, including viral vectors & plasmid DNA industry global market size, regional shares, competitors with a viral vectors & plasmid DNA market share, detailed viral vectors & plasmid DNA market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors & plasmid DNA industry. This viral vectors & plasmid DNA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the viral vectors and plasmid dna market include FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Каnеkа Соrроrаtіоn, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, Муlаn NV, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene.

North America was the largest region in the viral vectors and plasmid DNA market in 2024. The Middle East is expected to be the fastest growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the viral vectors and plasmid dna market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The viral vectors and plasmid DNA market consists of sales of adeno-associated viral, adenoviral, lentiviral, and retroviral. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.